and recommendation
bluebird Bio (BLUE)
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington.
BLUE’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. The company's lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma.
BLUE has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma (now Gilead). to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus. It also has strategic collaborations with Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications; and TC BioPharm to research and develop gamma delta CAR T cell product candidates for cancer immunotherapy.
BLUE was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
- April 2, 2024 - 3:16pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q3
- March 18, 2024 - 9:37am | Out and About, Research Notes, Out and About, Financings
- December 20, 2023 - 9:37am | Out and About, Research Notes, Out and About, Financings
- August 18, 2023 - 4:09pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings
- July 31, 2023 - 7:19am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q2
- May 27, 2023 - 12:37pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q1
- April 10, 2023 - 4:40pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
- January 18, 2023 - 10:19am | Out and About, Research Notes, Out and About, Financings
- January 9, 2023 - 1:49pm | Out and About, Research Notes, Out and About
- September 21, 2022 - 8:47pm | Out and About, Research Notes, Out and About
- August 16, 2022 - 11:38am | Out and About, Research Notes, Out and About
- September 23, 2021 - 7:10pm | Out and About, Research Notes, Out and About, Earnings Q2
- May 30, 2020 - 9:44am | Out and About, Research Notes, Out and About, Earnings Q1
- May 19, 2020 - 6:34am | Out and About, Research Notes, Out and About, Financings
- May 11, 2020 - 10:16am | Out and About, Research Notes, Out and About
- April 11, 2020 - 1:23pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
- January 29, 2019 - 12:50pm | Out and About, Out and About
- January 23, 2019 - 12:51pm | Out and About, Research Notes, Out and About
- January 22, 2019 - 1:13pm | Out and About, Research Notes, Out and About
- January 8, 2019 - 1:13pm | Out and About, Out and About